
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
FGEN | NASDAQ | USD | Real-time | |
FGEN | Mexico | MXN | Delayed | |
1FG0 | Frankfurt | EUR | Delayed |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
James A. Schoeneck | 67 | 2010 | Independent Chairman of the Board |
Thane Wettig | 60 | 2020 | CEO & Director |
Jeffrey L. Edwards | 64 | 2015 | Independent Director |
Maykin Ho | 72 | 2018 | Independent Director |
Michael Glen Kauffman | 61 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review